All In Biotech

Drug Trial Radar · NCT06973005

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

An Open-label, Fixed Sequence Study in Healthy Participants to Assess the Effect of Multiple Doses of AZD2389 on the Pharmacokinetics of Midazolam, Caffeine, and Bupropion

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

May 8, 2025

Primary completion

Jul 18, 2025

Study completion Jul 18, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.

Conditions

  • Advanced Chronic Liver Disease
  • Healthy Participants

Interventions

  • AZD2389Drug

    Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.

  • MidazolamDrug

    Single oral dose on: * Day 1 (co-administered with caffeine) * Day 14 (co-administered with caffeine and AZD2389)

  • CaffeineDrug

    Single oral dose on: * Day 1 (co-administered with midazolam) * Day 14 (co-administered with midazolam and AZD2389)

  • BupropionDrug

    Single oral dose on: * Day 2 (alone) * Day 15 (co-administered with AZD2389)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of treatment to reference based on Cmax (RCmax)Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
  2. Ratio of treatment to reference based on AUCinf (RAUCinf)Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
  3. Ratio of treatment to reference based on AUClast (RAUClast)Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
  4. Ratio of area under concentration-curve from time 0 to 24 hours post-dose (AUC0-24)Time frame: Period 1: Days 1-3; Period 3: Days 15-18.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Brooklyn, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.